$Rallybio Corp.(RLYB)$
The partnership with Johnson & Johnson not only includes a significant equity investment but also underscores a joint commitment to tackle this severe and rare disease. Rallybio's CEO, Stephen Uden, expressed enthusiasm about the collaboration, emphasizing its potential to drive awareness, accelerate research, and ultimately, eradicate FNAIT.
The collaboration between Rallybio and Johnson & Johnson represents a significant leap forward in addressing FNAIT, offering hope to pregnant individuals and their newborns. As Rallybio continues to drive innovation in therapeutic solutions, investors are optimistic about the company's potential to transform the landscape of rare disease treatment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- AgathaHume·04-12👍LikeReport
- PhoebeReade·04-12Nice one!LikeReport
- YueShan·04-13Good⭐️⭐️⭐️LikeReport